Business
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics t
About this update from Zymeworks Inc.
[{"type":"image","alt":"Zymeworks Inc.","displaySize":"","headline":null,"caption":"Zymeworks Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Mr3NL5l3JfRng99mnVVlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f","width":300,"height":107}},"lazy":false},{"type":"text","content":"Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile","length":146,"tagName":"p"},{"type":"text","content":"New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers","length":145,"tagName":"p"},{"type":"text","content":"VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the acceptance of six abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held April 24-30, 2025 in Chicago, IL.","length":522,"tagName":"p"},{"type":"text","content":"“As our wholly-owned pipeline continues to progress, we are excited to share updates at AACR on our novel multifunctional therapeutics addressing difficult-to-treat cancers,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E-targeting antibody-drug conjugate incorporating our proprietary topoisomerase 1 inhibitor payload, ZD06519. These preclinical findings demonstrate how our therapeutic approaches have the potential to improve outcomes for patients with currently limited treatment options.”","length":711,"tagName":"p"},{"type":"text","content":"Poster Presentation Details","length":27,"tagName":"p"},{"type":"text","content":"T cell Engagers:","l...